NCT03681457View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

September 25, 2019

Study Completion Date

September 25, 2019

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

LJN452

Dose A single dose

Trial Locations (3)

32806

Novartis Investigative Site, Orlando

32809

Novartis Investigative Site, Orlando

37920

Novartis Investigative Site, Knoxville

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY